XB-002 is under clinical development by Exelixis and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XB-002 overview
XB-002 is under development for the treatment of solid tumors including peritoneal cancer, fallopian tube cancer, non-small cell lung cancer, epithelial ovarian cancer, cervical cancer, pancreatic cancer and head and neck cancer squamous cell carcinoma esophageal, metastatic castrate resistant prostate cancer (mCRPC), triple negative breast cancer (TNBC), colorectal cancer, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, endometrial cancer, human epidermal growth factor receptor 2 negative breast cancer and hormone receptor-positive breast cancer. It is administered through intravenous route in the form of solution. The drug candidate is a second generation antibody drug conjugate which acts by targeting the tissue factor (TF). It is being developed based on ZymeLink Auristatin and ZymeLink Hemiasterlin technology.
It was also under development for urothelial cancer including renal pelvis, ureter, urinary bladder cancer, urethral cancer.
Exelixis overview
Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The company’s major pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors, and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
For a complete picture of XB-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
